Congenital muscular dystrophy
- Congenital MD
News & Events
NCATS Co-Sponsored Conferences
American Society of Gene & Cell Therapy (ASGCT) 19th Annual Meeting, Wednesday, May 04, 2016 - Saturday, May 07, 2016
Location: Washington, DC
Description: Save the date and plan to head to Washington, DC on May 4-7, 2016, for the premiere gene and cell therapy conference in the world. Taking place at the Marriott Wardman Park Hotel, the ASGCT 19th Annual Meeting will feature ground breaking clinical trial results, cutting edge technology advancements, social networking events, and much more. Join over 1,900 of the worlds top gene and cell therapy professionals for four full days of educational offerings including plenary lectures given by Dr. David R. Liu and 2015 Japan Prize recipients, Dr. Alain Fischer, and Dr. Theodore Friedmann.
New Directions in Biology and Disease of Skeletal Muscle, Sunday, June 29, 2014 - Wednesday, July 02, 2014
Location: Chicago, IL
Description: The goals of the New Directions conference are to: (1) provide a unique forum for presentation and sharing of unpublished data, (2) promote collaboration between industry and academic investigators, (3) provide an interactive forum for clinical trial planning and outcome measure development, (4) facilitate the identification of both common and unique targets for each neuromuscular disease, and (5) provide trainees and young investigators a forum in which to present data and to encourage trainees to remain studying neuromuscular disease.
Congenital Muscular Dystrophy: From Clinical Pathology to Underlying Scientific Mechanisms, Exploring the Role of the Myomatrix, Sunday, April 22, 2012 - Tuesday, April 24, 2012
Location: University of Nevada School of Medicine, Center for Molecular Medicine, Reno, NV
Description: The goals of the conference are to: 1) Establish the current state of knowledge in different myomatrix research areas germane to the CMDs and to dystrophic pathology, 2) Explore novel mechanisms, intersections and crosstalk of relevant mechanisms and perform comparative analysis across disease models, 3) Design effective strategies and platforms to pursue treatment development for key aspects of CMD clinical pathology to drive future translational opportunities